BioN­Tech signs im­munother­a­py deal with Medi­gene as post-Covid strat­e­gy takes shape

Con­tin­u­ing to chart its path for­ward post-pan­dem­ic, BioN­Tech struck a new deal Mon­day aimed at boost­ing its pres­ence in on­col­o­gy.

The Covid-19 vac­cine mak­er signed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER